Article
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Genetics in medicine : official journal of the American College of Medical Genetics - 1 Jan 2009
Palomaki Glenn E, Bradley Linda A, Douglas Michael P, Kolor Katherine, Dotson W David
Abstract excerpt
This evidence-based review addresses the question of whether testing for UGT1A1 mutations in patients with metastatic colorectal cancer treated with irinotecan leads to improvement in outcomes (e.g., irinotecan toxicity, response to treatment, morbidity, and mortality), when compared with no testing. No studies were identified that addressed this question directly. The quality of evidence on the analytic validity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.